Oct 23, 2019
Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
Oct 22, 2019
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
Oct 14, 2019
Global RNA Interference (RNAi) Industry
Oct 10, 2019
Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
Oct 09, 2019
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Oct 07, 2019
Visiongain Report Looks at Opportunities Within the $257bn Rare Disease Drugs Market
Sep 17, 2019
Positive preliminary results from ATL1102 for DMD Phase II trial
Sep 11, 2019
Dynacure to Present at Chardan's 3rd Annual Genetic Medicines Conference
Sep 04, 2019
Locana appoints Kathie Bishop, Ph.D., as Chief Scientific Officer
Sep 03, 2019
Dynacure Appoints David Garrett as Chief Financial Officer
Aug 27, 2019
Ionis licenses hepatitis B program to GSK
Aug 08, 2019
Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'
Aug 07, 2019
Ionis Reports Second Quarter 2019 Financial Results
Jul 30, 2019
Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
Jul 01, 2019
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
May 01, 2019
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Apr 30, 2019
Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'
Mar 25, 2019
Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
Mar 07, 2019
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 04, 2019
PTC to Expand Product Portfolio in Latin America with WAYLIVRA(TM)